William A. Ackman is sitting on a paper profit of more than $1 billion after he and Valeant Pharmaceuticals made an unsolicited bid for Allergan, leaving some to wonder whether the windfall comes as result of what feels like insider trading, writes William D. Cohan. Read Full Article